The rising prevalence of chronic and infectious diseases in Canada and the U.S. is creating an urgent need for rapid, decentralized diagnostic solutions that enable timely detection and effective disease management. With increasing cases of conditions such as diabetes, cardiovascular diseases, respiratory infections, and sexually transmitted infections across both countries, traditional centralized laboratory testing is often too slow or inaccessible for many patients—particularly in underserved or rural communities. Point-of-Care Testing (POCT) technologies offer a faster, more convenient alternative by delivering immediate results near the patient, which is critical for initiating prompt treatment, reducing disease progression, and improving overall care outcomes., Healthcare providers and policymakers in both Canada and the U.S. are increasingly recognizing the value of POCT in addressing the growing disease burden, especially in community health centers, urgent care settings, and remote regions where access to centralized labs is limited. This rising demand is driving public and private investments in advanced diagnostic platforms that support rapid clinical decision-making. Additionally, the COVID-19 pandemic catalyzed widespread adoption of decentralized testing solutions, accelerating the deployment of POCT technologies across hospitals, pharmacies, and other healthcare facilities throughout North America. As health systems continue to focus on accessibility, early detection, and value-based care, the need for efficient, near-patient diagnostics is expected to remain a key growth driver in the market.

Profitez des vidéos et de la musique que vous aimez, mettez en ligne des contenus originaux, et partagez-les avec vos amis, vos proches et le monde entier.